Literature DB >> 25462555

Antiviral and metabolic gene expression responses to viral infection in Atlantic salmon (Salmo salar).

Zeynab Heidari1, John Tinsley2, Ralph Bickerdike2, Marian F McLoughlin3, Jun Zou1, Samuel A M Martin4.   

Abstract

Salmonid alphavirus (SAV), the aetiological agent of pancreas disease, is recognized as a serious pathogen of farmed Atlantic salmon. This disease results in loss of weight followed by poor growth of surviving fish, as such it is viewed as a wasting disease. SAV and other chronic disease causing viruses affect the heart and skeletal muscle tissues, at present the mechanisms by which pathology occurs is unknown. The relationship between antiviral activity and other physiological parameters especially in skeletal muscle are currently not examined in depth in fish. An experimental SAV (isotype 3) infection was carried out using a cohabitation approach, from which samples were collected at 0, 4, 8 & 12 week post challenge. Maximum viral load in the muscle tissue was 4 weeks post infection which was reduced at 8 weeks and undetectable by 12 weeks. Histopathology score peaked at 4 weeks post infection in pancreas and heart whereas there was maximum damage in skeletal muscle at 8 weeks. The peak expression of antiviral immune genes coincided with the viral load. Several genes involved in protein degradation were increased following infection including atrogin-1 and cathepsin D, at 4 weeks post challenge suggesting reallocation of amino acid reserves. Taken together, these observations increase our understanding of salmon poor growth during viral infection, and will serve as a basis to develop strategies to manage this viral wasting disease.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Atlantic salmon; Atrogin-1; Gene expression; SAV; Salmonid alphavirus

Mesh:

Substances:

Year:  2014        PMID: 25462555     DOI: 10.1016/j.fsi.2014.11.003

Source DB:  PubMed          Journal:  Fish Shellfish Immunol        ISSN: 1050-4648            Impact factor:   4.581


  5 in total

1.  Relationship between viral dose and outcome of infection in Atlantic salmon, Salmo salar L., post-smolts bath-challenged with salmonid alphavirus subtype 3.

Authors:  Jiraporn Jarungsriapisit; Lindsey J Moore; Stig Mæhle; Cecilie Skår; Ann Cathrine Einen; Ingrid Uglenes Fiksdal; Hugh Craig Morton; Sigurd O Stefansson; Geir Lasse Taranger; Sonal Patel
Journal:  Vet Res       Date:  2016-10-19       Impact factor: 3.683

2.  Effects of Vitamin D2 (Ergocalciferol) and D3 (Cholecalciferol) on Atlantic Salmon (Salmo salar) Primary Macrophage Immune Response to Aeromonas salmonicida subsp. salmonicida Infection.

Authors:  Manuel Soto-Dávila; Katherinne Valderrama; Sabrina M Inkpen; Jennifer R Hall; Matthew L Rise; Javier Santander
Journal:  Front Immunol       Date:  2020-01-14       Impact factor: 7.561

3.  Structural Insights into the Mechanisms of Action of Functionally Distinct Classes of Chikungunya Virus Nonstructural Protein 1 Inhibitors.

Authors:  Kristina Kovacikova; Marina Gorostiola González; Rhian Jones; Juan Reguera; Alba Gigante; María-Jesús Pérez-Pérez; Gerhard Pürstinger; Julia Moesslacher; Thierry Langer; Lak Shin Jeong; Leen Delang; Johan Neyts; Eric J Snijder; Gerard J P van Westen; Martijn J van Hemert
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

4.  Atlantic salmon (Salmo salar L.) post-smolts challenged two or nine weeks after seawater-transfer show differences in their susceptibility to salmonid alphavirus subtype 3 (SAV3).

Authors:  J Jarungsriapisit; L J Moore; G L Taranger; T O Nilsen; H C Morton; I U Fiksdal; S Stefansson; P G Fjelldal; Ø Evensen; S Patel
Journal:  Virol J       Date:  2016-04-11       Impact factor: 4.099

5.  Rainbow trout (Oncorhynchus mykiss) muscle satellite cells are targets of salmonid alphavirus infection.

Authors:  Stéphane Biacchesi; Grégory Jouvion; Emilie Mérour; Abdelhak Boukadiri; Marion Desdouits; Simona Ozden; Michel Huerre; Pierre-Emmanuel Ceccaldi; Michel Brémont
Journal:  Vet Res       Date:  2016-01-08       Impact factor: 3.683

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.